VTN and neoplasm: THL has been shown to inhibit adhesion to vitronectin and tumor-induced angiogenesis in vivo by decreasing paxillin in human umbilical vein endothelial cells (HUVECs) (Minamiguchi et al., 2001); and to block Hsp27 phosphorylation by inducing endothelial cell adhesion and wound/tumor-driven angiogenesis in vitro (Jia et al., 2010).